If you have been reading about Lipodystrophy and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
The Byzantine Empire distinctively blended Roman political traditions, Greek literary heritage, and Christianity, creating the civilisational framework that laid the foundation for medieval Europe. The Empire preserved European civilisation by acting as a shield against forces from Eurasian Steppe people such as the Avars, Bulgars, Cumans, Huns, Pechenegs, and Turks. The empire's legal codes significantly influenced the civil law traditions of continental Europe, Russia, Latin America, Ethiopia, and even the English-speaking common law countries; and possibly influenced Islamic legal traditions as well. It also preserved and transmitted classical learning and manuscripts, making important contributions to the intellectual revival which fuelled Italian humanism. The Byzantine Empire played a pivotal role in shaping Christianity by supporting early Church fathers and the decisions of Church councils; developing the institution of monasticism; and fostering the Orthodox tradition which continues to define much of Eastern European identity. It was also instrumental in preserving the Greek language and is credited with developing the Glagolitic alphabet, which later evolved into the Cyrillic script and Old Church Slavonic. These innovations provided the first literary language for the Slavs and formed the educational foundation for all Slavic nations.
== Use as feed == Biuret is used as a non-protein nitrogen source in ruminant feed, where it is converted into protein by gut microorganisms. It is less favored than urea, due to its higher cost and lower digestibility but the latter characteristic also slows down its digestion and so decreases the risk of ammonia toxicity.
=== Mutations === Mutations in myostatin do more than just affect the amount of muscle mass an organism can produce; they also have variable effects on other phenotypes for different species. For example, a Belgian Blue bovine with a mutation that inhibits myostatin production will exhibit a dramatic increase in muscle mass but will also lead to dystocia. Other species with myostatin deficiency mutation such as humans or Whippet dogs do not get obstructed labor.
== EMAIL invention controversy == Ayyadurai is notable for his widely disputed claim of being the "inventor of email". His claim is based on an electronic mail software called EMAIL, an implementation of interoffice email system, which he wrote as a 14-year-old student at Livingston High School, New Jersey, in 1979. Initial reports that repeated Ayyadurai's assertion—from organizations such as The Washington Post and the Smithsonian Institution—were followed by public retractions. These corrections were triggered by objections from historians and ARPANET pioneers who cited the fact the history of email dated back to the early 1970s. Ayyadurai started a campaign in 2011 in which he rebranded himself as the "Inventor of Email"; according to a paper published in Information & Culture, he "provoked a dramatic succession of exaggerated claims, credulous reporters, retractions, and accusations that a cabal of industry insiders and corrupt Wikipedia editors are colluding to hide the truth." A November 2011 Time Techland interview by Doug Aamoth, entitled "The Man Who Invented Email", argued that EMAIL represented the birth of email "as we currently know it". In that interview, Ayyadurai recalled that Les Michelson, the former particle scientist at Brookhaven National Labs who assigned Ayyadurai the project, had the idea of creating an electronic mail system that uses the header conventions of a hardcopy memorandum. Ayyadurai recalled Michelson as saying: "Your job is to convert that into an electronic format.
== History == Robert Vince and Susan Daluge along with Mei Hua, a visiting scientist from China, developed the medication in the '80s. Abacavir was approved by the US Food and Drug Administration (FDA) in December 1998 and is the fifteenth approved antiretroviral drug in the United States.
Sources: en.wikipedia.org
Episode Two followed in 2007, alongside the multiplayer game Team Fortress 2 and the puzzle game Portal, developed from the student project Narbacular Drop. In February 2007, Valve announced The Black Box and The Orange Box, both bundles of multiple games and expansions, to be distributed by Electronic Arts for Microsoft Windows, PlayStation 3 and Xbox 360. In January 2008, Valve announced the acquisition of Turtle Rock Studios, which was renamed Valve South. Turtle Rock developed Left 4 Dead and Left 4 Dead 2 while associated with Valve. Turtle Rock Studios spun out of Valve again in March 2010. Forbes estimated that Valve had grossed $70 million in 2005.
Carboxypeptidase E (CPE), also known as carboxypeptidase H (CPH) and enkephalin convertase, is an enzyme that in humans is encoded by the CPE gene. This enzyme catalyzes the release of C-terminal arginine or lysine residues from polypeptides. CPE is involved in the biosynthesis of most neuropeptides and peptide hormones. The production of neuropeptides and peptide hormones typically requires two sets of enzymes that cleave the peptide precursors, which are small proteins. First, proprotein convertases cut the precursor at specific sites to generate intermediates containing C-terminal basic residues (lysine and/or arginine). These intermediates are then cleaved by CPE to remove the basic residues. For some peptides, additional processing steps, such as C-terminal amidation, are subsequently required to generate the bioactive peptide, although for many peptides the action of the proprotein convertases and CPE is sufficient to produce the bioactive peptide.
== Signs and symptoms == Hyperthyroidism may be asymptomatic or present with significant symptoms. Some of the symptoms of hyperthyroidism include nervousness, irritability, increased perspiration, heart racing, hand tremors, anxiety, trouble sleeping, thinning of the skin, fine brittle hair, and muscular weakness—especially in the upper arms and thighs. More frequent bowel movements may occur, and diarrhea is common. Weight loss, sometimes significant, may occur despite a good appetite (though 10% of people with a hyperactive thyroid experience weight gain), vomiting may occur, and, for women, menstrual flow may lighten and menstrual periods may occur less often, or with longer cycles than usual.
In animal and Human biology, a tendon cell is a cell that makes up tendons, the bands of connective tissue that connects muscles to bones. Tendon cells, also known as tenocytes or tendon fibroblasts, are specialized cells that contribute to the structure, function, and repair of tendons in the body. Tendons are fibrous tissues that connect muscles to bones, and tendon cells play a vital role in maintaining tendon homeostasis and facilitating healing following injury.
Sources: en.wikipedia.org
Wise (1916), attorney and director of the American Civil Liberties Union Horace Manges (1917), attorney, name partner of Weil, Gotshal & Manges Benjamin Buttenwieser (1919), partner of Kuhn, Loeb, president of the United Jewish Appeal, grandson-in-law of Mayer Lehman and Adolph Lewisohn Alfred Egidio Modarelli (1920), judge on the United States District Court for the District of New Jersey George Rosling (1920), judge on the United States District Court for the Eastern District of New York Archie Owen Dawson (1921), judge of the United States District Court for the Southern District of New York Louis Nizer (1922), legendary trial lawyer who wrote My Life in Court Joseph Carmine Zavatt (1922), judge of the United States District Court for the Eastern District of New York Alan J. Altheimer (1923), lawyer and managing partner of Altheimer & Gray Milton Handler (1923), antitrust expert and Columbia Law School professor John T. Cahill (1924), U.S. attorney for the Southern District of New York and founding partner of Cahill Gordon & Reindel Paul R.
=== Passive products === Generally, these products are indicated for only superficial, clean, and dry wounds with minimal exudates. They can also be used as secondary dressings (additional dressings to secure the primary dressing in place or to absorb additional discharge from the wound). Examples are: Gauze, lint, adhesive bandage (plasters), and cotton wool. The main aim is to protect the wound from bacterial contamination. They are also used for secondary dressing. Gauze dressing is made up of woven or non-woven fibres of cotton, rayon, and polyester. Gauze dressing are capable of absorbing discharge from wound but requires frequent changing. Excessive wound discharge would cause the gauze to adhere to the wound, thus causes pain when trying to remove the gauze from the wound. Bandages are made up of cotton wool, cellulose, or polyamide materials. Cotton bandages can act as a secondary dressing while compression bandages provides good compressions for venous ulcers. On the other hand, tulle gras dressing which is impregnated with paraffin oil is indicated for superficial clean wound.
As sugar could not have been easily formed under the extreme environment of early Earth, it has been suggested that certain sugars may have originated from space. Astronomers postulate that asteroids delivered sugars to Earth, or sugars were always present in the Solar System. In 2000, astronomers detected glycolaldehyde—a sugar-like molecule—in interstellar space. True sugar was first collected from an asteroid in 2019. Sugar was also detected in a sample collected from the asteroid 101955 Bennu in 2020. In 2026, erythrulose—a tetrose monosaccharide—was detected in dust grains of a molecular cloud near the center of the Milky Way, marking the first time a sugar molecule was found in interstellar space. The identification of erythrulose in galactic dust indicates its possible involvement in forming sugar-containing nucleic acids during the origin of life on Earth about four billion years ago.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.